Phase II Trial Evaluating the Efficacy of Moderna COVID-19 Vaccine Booster Dosing in Patients With Hematologic Malignancies Who Did Not Have an Adequate Response to Prior Vaccination
Latest Information Update: 23 Nov 2023
At a glance
- Drugs Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 30 Oct 2023 Status changed from active, no longer recruiting to completed.
- 24 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2022 Planned End Date changed from 31 Jan 2023 to 21 Jul 2023.